---
title: "Follow-up Colonoscopy After Abnormal Stool-Based CRC Screening: Completion, Timeliness and Impleme"
id: "bmj-open-21-follow-up-colonoscopy-after-abnormal-stool-based-colorectal-cancer-screening-a"
canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-21-follow-up-colonoscopy-after-abnormal-stool-based-colorectal-cancer-screening-a"
content_type: "clinical_feed_article"
specialty: "Gastroenterology"
source_name: "BMJ Open"
source_url: "http://bmjopen.bmj.com/cgi/content/short/16/10/e115052?rss=1"
published_at: "2026-10-05T12:12:55.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Follow-up Colonoscopy After Abnormal Stool-Based CRC Screening: Completion, Timeliness and Impleme
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-21-follow-up-colonoscopy-after-abnormal-stool-based-colorectal-cancer-screening-a
- **Specialty:** [Gastroenterology](https://medichelpline.com/clinical-feed/gastroenterology.md)
- **Primary Source:** BMJ Open
- **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/10/e115052?rss=1)
- **Published At:** 2026-10-05T12:12:55.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This systematic review synthesized evidence on diagnostic **colonoscopy completion** and **time to colonoscopy** after abnormal stool-based colorectal cancer screening tests, covering studies from 2010 to 28 October 2025. - Included study designs comprised randomised and non-randomised trials, observational and mixed-methods studies and programme evaluations involving adults with abnormal faecal immunochemical test (FIT), guaiac faecal occult blood test (gFOBT) or multitarget stool DNA-FIT results. - Outcomes extracted were colonoscopy completion, time-to-colonoscopy, implementation strategies and sociodemographic differences; risk of bias and certainty (GRADE) were assessed. - Twenty-five studies were included, mostly from high-income settings; reported follow-up intervals were grouped approximately into ≤3, ≤6 and ≤12 months. - Reported **colonoscopy completion** varied by setting: ~30%–55% within 6–12 months in federally qualified health centres and safety-net settings, versus 70%–80% or higher in organised and integrated programmes. - Observed **time to colonoscopy** ranged roughly from 42 to 184 days across studies. - Higher completion rates and shorter delays were more often seen in programmes that used registry-based tracking, clearly assigned responsibility for abnormal results, proactive outreach or **navigation**, and coordinated colonoscopy scheduling. - Of 25 studies, one had low overall risk of bias, 19 moderate and five serious risk; certainty of evidence was low for ~6- and ~12-month completion and very low for ~3-month completion and time to colonoscopy. - Authors conclude that pathways combining tracking, ownership of results, outreach/navigation and integrated scheduling tended to perform better, but heterogeneous and predominantly observational evidence limits confidence in comparative effectiveness of specific implementation bundles. - The review highlights that health systems serving under-resourced populations may need targeted investment in tracking, navigation and integrated scheduling to improve timely and equitable follow-up after abnormal stool-based screening.
## Clinical Analysis & Structured Key Points
Objectives To synthesise evidence on diagnostic colonoscopy completion and time-to-colonoscopy after abnormal stool-based colorectal cancer screening tests and to examine the implementation strategies and health-system configurations used to support follow-up. Design Systematic review with narrative synthesis, reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement and the Synthesis Without Meta-analysis reporting guideline. Data sources We searched MEDLINE via PubMed, Embase via Ovid and Scopus for articles published from 1 January 2010 to 28 October 2025. Reference lists of included studies were also screened. Eligibility criteria Randomised and non-randomised trials, observational studies, mixed-methods studies and eligible programme evaluations involving adults with an abnormal faecal immunochemical test, guaiac faecal occult blood test or multitarget stool DNA-faecal immunochemical test were included. Eligible studies reported diagnostic colonoscopy completion, time to colonoscopy or implementation-related outcomes. Data extraction and synthesis Study characteristics, implementation strategies, colonoscopy completion, time-to-colonoscopy and sociodemographic differences were extracted using a piloted form. Risk of bias was assessed using the Revised Cochrane risk-of-bias tool for randomised trials, the Risk of Bias in Non-randomised Studies of Interventions or the Joanna Briggs Institute tools, according to study design. Certainty of evidence was assessed using Grading of Recommendations, Assessment, Development and Evaluation (GRADE). Because of differences in settings, study designs and outcome definitions, findings were synthesised narratively. Reported follow-up intervals were grouped into approximately ≤3, ≤6 and ≤12 months. Results Twenty-five studies were included, predominantly from high-income settings. Colonoscopy completion within 6 - 12 months commonly ranged from approximately 30% to 55% in federally qualified health centres and safety-net settings to 70% - 80% or higher in organised and integrated programmes. Time to colonoscopy ranged from approximately 42 to 184 days. Higher completion and shorter delays were more commonly reported in programmes combining real-time tracking, clearly assigned responsibility, proactive outreach or navigation and coordinated colonoscopy scheduling. Of the 25 studies, 1 was judged to have low overall risk of bias, 19 moderate risk and 5 serious risk. Certainty of evidence was low for colonoscopy completion at approximately 6 and 12 months and very low for approximately 3-month completion and time to colonoscopy. Conclusions Higher-performing post-abnormal-test pathways commonly incorporated registry-based tracking, clear ownership of abnormal results, proactive outreach or navigation and coordinated access to colonoscopy. However, confidence in the comparative performance of specific implementation bundles is limited by heterogeneous and predominantly observational evidence. Health systems serving under-resourced populations may require targeted investment in tracking, navigation and integrated scheduling to improve timely and equitable follow-up. PROSPERO registration number PROSPERO CRD42024579672.
## Related Clinical Research

- [IBDex frozen atlas converts bulk transcriptomics into reusable IBD reference](https://medichelpline.com/clinical-feed/medrxiv-17-ibdex-a-frozen-patient-scale-atlas-for-bulk-transcriptomics-in-inflammatory.md)
- [Inulin-driven gut microbiome changes increase sporadic colon cancer susceptibility in mice](https://medichelpline.com/clinical-feed/biorxiv-8-dietary-fiber-type-specific-gut-microbiome-preconditioning-drives-differential.md)
- [Genomic alterations in histologically clear dysplasia margins predict advanced neoplasia in ulcera](https://medichelpline.com/clinical-feed/medrxiv-7-genomic-alterations-in-histologically-clear-low-grade-dysplasia-resection.md)
- [Author correction: SCREESCO trial cumulative incidence estimates for colorectal cancer screening a](https://medichelpline.com/clinical-feed/nature-3-author-correction-colonoscopy-and-fecal-immunochemical-testing-versus-usual.md)
- [CBC-derived inflammatory indices in colorectal cancer: diagnostic and prognostic head-to-head anal](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-complete-blood-count-derived-inflammation-indices-in-colorectal-cancer-head-to.md)

## Navigation
- [← Back to Gastroenterology Feed](https://medichelpline.com/clinical-feed/gastroenterology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.